From mitochondrial cristae pathobiology to metabolic reprogramming in cancer: the α and ω of Malignancies?

Vista sencilla de ítem
dc.contributor.authorArismendi Morillo, Gabriel J.
dc.contributor.authorDuraj, Tomás
dc.contributor.authorLee, Derek C.
dc.contributor.authorMukherjee, Purna
dc.contributor.authorSeyfried, Thomas N.
dc.date.accessioned2026-04-20T08:28:34Z
dc.date.available2026-04-20T08:28:34Z
dc.date.issued2025-11-14
dc.date.updated2026-04-20T08:28:34Z
dc.description.abstractMitochondrial cristae pathobiology, involving partial or total cristolysis, is a hallmark of human and mammalian cancer. This feature represents the basis of metabolic dysfunction in neoplastic cells. Consequently, most cancer cells with mitochondrial cristae defects would be incapable of producing adequate amounts of energy through oxidative phosphorylation. ATP production through increased glucose-driven cytosolic and glutamine-driven mitochondrial substrate-level phosphorylation thus becomes necessary to compensate for OxPhos insufficiency. The aim of this article is to offer a brief perspective on the link between the mitochondrial cristae pathobiology and the metabolic reprogramming in cancer cells, whose origin is linked to chronic mitochondrial cristae lesion (named α) and its eventual resolution by means of a progressive and continuous process of tumor cell death (named ω), induced by metabolic targeting. Dietary and pharmacological metabolic therapies that restrict the utilization of glucose and glutamine in tumor cells while elevating circulating ketone bodies represent a non-toxic therapeutic strategy for cancer management. Metabolic therapy can induce a persistent state of energy stress with a consequent increase in tumor cell death and reduction of tumor mass while improving the energy efficiency of non-neoplastic cells. Recent clinical studies suggest that ketogenic metabolic therapies may be therapeutically useful and well-tolerated in the long term.en
dc.identifier.citationArismendi-Morillo, G., Duraj, T., Lee, D. C., Mukherjee, P., & Seyfried, T. N. (2025). From mitochondrial cristae pathobiology to metabolic reprogramming in cancer: the α and ω of Malignancies?. Oncologie, 27(6), 1065-1073. Walter de Gruyter GmbH. https://doi.org/10.1515/ONCOLOGIE-2025-0379
dc.identifier.doi10.1515/ONCOLOGIE-2025-0379
dc.identifier.eissn1765-2839
dc.identifier.issn1292-3818
dc.identifier.urihttps://hdl.handle.net/20.500.14454/5705
dc.language.isoeng
dc.publisherWalter de Gruyter GmbH
dc.rights© 2025 the author(s), published by De Gruyter on behalf of Tech Science Press (TSP)
dc.subject.otherLipid droplets
dc.subject.otherMitochondrial cristae
dc.subject.otherOxygen consumption
dc.subject.otherSubstrate-level phosphorylation
dc.titleFrom mitochondrial cristae pathobiology to metabolic reprogramming in cancer: the α and ω of Malignancies?en
dc.typereview article
dcterms.accessRightsopen access
oaire.citation.endPage1073
oaire.citation.issue6
oaire.citation.startPage1065
oaire.citation.titleOncologie
oaire.citation.volume27
oaire.licenseConditionhttps://creativecommons.org/licenses/by/4.0/
oaire.versionVoR
Archivos
Bloque original
Mostrando 1 - 1 de 1
Miniatura
Nombre:
arismendi_from_2025.pdf
Tamaño:
8.54 MB
Formato:
Adobe Portable Document Format
Descargar
Colecciones
Artículos